Generic Name

Glulisine

Brand Names
Apidra, Apidra SoloStar
FDA approval date: February 24, 2009
Classification: Insulin Analog
Form: Injection

What is Apidra (Glulisine)?

APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. APIDRA is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.
(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.
Journal: The Cochrane database of systematic reviews
Published: June 19, 2026
Regular human insulins versus rapid-acting insulin analogues in children and adolescents with type 1 diabetes: a systematic review with meta-analysis and trial sequential analysis.
Regular human insulins versus rapid-acting insulin analogues in children and adolescents with type 1 diabetes: a systematic review with meta-analysis and trial sequential analysis.
Journal: BMJ open
Published: May 14, 2026
Delayed Hypersensitivity Reaction to Insulin: A Case Report.
Delayed Hypersensitivity Reaction to Insulin: A Case Report.
Journal: Cureus
Published: May 05, 2026
View All Latest Advances

Brand Information